Additional Her 2/neu gene copies in patients with Sézary syndrome

Leuk Res. 2006 Jun;30(6):755-60. doi: 10.1016/j.leukres.2005.10.012. Epub 2005 Nov 21.

Abstract

Background: Her 2/neu gene amplification has been reported in several types of cancer. Monoclonal antibodies against the Her 2/neu receptor are used as a treatment in e.g. metastatic breast cancer.

Aim: The aim of this study was to determine the frequency of additional Her 2/neu gene copies in relations to the number of chromosome 17 centromeres of patients with Sézary syndrome.

Methods: Fluorescence in situ hybridization (FISH) with probes specific for the Her 2/neu gene locus and the centromere of chromosome 17 was performed on nuclei from peripheral blood cells of 9 patients with Sézary syndrome. For analysis of Her 2/neu protein expression immunostaining was performed. In addition, FISH was used to analyze distribution of typical lymphocytes on cryo-cut sections of affected skin of two patients.

Results: 7/9 cases showed additional Her 2/neu gene copies in relation to the number of chromosome 17 centromeres. 4/5 cases with additional Her 2/neu gene copies in which immunostaining was performed expressed Her 2/neu protein. On cryo-cut sections atypical lymphocytes with additional Her 2/neu gene copies were detected in the dermis as well as in the epidermis of affected skin.

Discussion: These data suggest that Her 2/neu might be involved in the pathogenesis of Sézary syndrome and that Her 2/neu might be a promising target for antitumor therapy in a subgroup of patients.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Centromere / genetics*
  • Chromosomes, Human, Pair 17 / genetics*
  • Female
  • Gene Amplification / genetics*
  • Genes, erbB-2 / genetics*
  • Humans
  • In Situ Hybridization, Fluorescence
  • Male
  • Middle Aged
  • Sezary Syndrome / drug therapy
  • Sezary Syndrome / genetics*
  • Sezary Syndrome / pathology
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / genetics*
  • Skin Neoplasms / pathology